Seres Therapeutics' Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

Author's Avatar
Feb 14, 2023

Seres+Therapeutics%2C+Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of data from its Phase 3 ECOSPOR IV trial (ClinicalTrials.gov Identifier: NCT03183128) in JAMA Network Open that reinforce previously published results from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI). With nearly 156,000 cases in the U.S., rCDI is a leading cause of hospital-acquired infection and places a significant burden on the healthcare system.